VENTOLIN NEBULES P.F. - 2.5MG/2.5ML SOLUTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

SALBUTAMOL (SALBUTAMOL SULFATE)

Disponibbli minn:

GLAXOSMITHKLINE INC

Kodiċi ATC:

R03AC02

INN (Isem Internazzjonali):

SALBUTAMOL

Dożaġġ:

2.5MG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

SALBUTAMOL (SALBUTAMOL SULFATE) 2.5MG

Rotta amministrattiva:

INHALATION

Unitajiet fil-pakkett:

2.5 ML DOSE X 20

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0108887007; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2022-07-05

Karatteristiċi tal-prodott

_ _
_ _
_Page 1 of 33_
_ _
PRODUCT MONOGRAPH
PR
VENTOLIN
RESPIRATOR SOLUTION
salbutamol sulfate solution
5 mg/mL
PR
VENTOLIN NEBULES P.F.
salbutamol sulfate solution
2.5 mg/2.5 mL, 5 mg/2.5 mL ampoules
Bronchodilator
(beta
2
-adrenergic agonist)
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
November 17, 2017
Submission Control No: 207158
© 2017 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK
group of companies.
_ _
_ _
_Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................15
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL INFORMATION
.........................................................